Rhenman & Partners Asset Management AB

Position in MDGL — Madrigal Pharmaceuticals, Inc.

CIK 1599882 Stockholm, V7

Position in MDGL

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$12,589,453

+$1,204,706 QoQ

Shares Held

24,050

+23.0% QoQ

Ownership

0.104%

of shares outstanding

% of Portfolio

1.55%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2023

7 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Rhenman & Partners Asset Management AB holds $297,378,771 across 37 Biotechnology names. MDGL ranks #5 (4.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	48,100	$37,163,984
2	INSM	INSMED Inc	159,760	$26,123,955
3	VRTX	Vertex Pharmaceuticals Inc / Ma	43,485	$19,417,791
4	JAZZ	Jazz Pharmaceuticals plc	75,890	$14,347,004
5	MDGL	Madrigal Pharmaceuticals, Inc. This page	24,050	$12,589,453
6	BMRN	Biomarin Pharmaceutical Inc	207,000	$11,693,430
7	ALNY	Alnylam Pharmaceuticals, Inc.	34,465	$11,403,434
8	RPRX	Royalty Pharma plc	233,000	$11,177,010

7 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$12,589,453	24,050	+23.0%	Shares	Sole	2026-05-14
2025-12-31	$11,384,747	19,550	+7.1%	Shares	Sole	2026-02-13
2025-09-30	$8,370,545	18,250	+19.3%	Shares	Sole	2025-11-13
2024-09-30	$3,246,966	15,300	-42.3%	Shares	Sole	2024-11-13
2024-06-30	$7,424,240	26,500	-27.4%	Shares	Sole	2024-08-13
2024-03-31	$9,746,960	36,500	+62.2%	Shares	Sole	2024-05-14
2023-12-31	$5,206,050	22,500	—	Shares	Sole	2024-02-13
No filing history on record for this holder in this stock.